Treatment of @entity263 with the combination of @entity585 plus XXXX : early results.

@entity1 @entity251 @entity263 @entity585 @entity12194 @entity247 @entity10831 @entity342
In an attempt to maximize the quality of life of @entity263 @entity1 on prolonged total @entity342 ablation and to minimize side effects, we have devised a strategy of 'sequential @entity342 blockade'. Animal studies have demonstrated that the combination of the @entity10831 inhibitor @entity585 and the antiandrogen @entity12194 was as effective as a luteinizing hormone-releasing hormone analog and @entity12194 in inhibiting the growth of the prostate. In a pilot trial, 10 potent @entity1 with clinical stage C and @entity263 were given the combination of @entity585 (5 mg b.i.d.) and @entity12194 (125-250 mg t.i.d.). Eight of ten @entity1 remained potent. At 3 months the mean prostate-specific antigen level of all @entity1 was 3.8 ng/ml (34 ng/ml prior to therapy). In all patients serum @entity251 increased and those with the highest increase demonstrated @entity247 . The combination was easily tolerable and side effects were few. This treatment regime appears to offer the benefits of total @entity342 blockade, is less expensive and has fewer side effects. Further trials are warranted.
